Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
At retirement, target date funds typically rebalance toward conservative assets, adjusting to support withdrawals while aiming to preserve principal.
20,347 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
New York Governor Hochul’s decision to pause autonomous for-hire vehicle expansion outside NYC hits Waymo and Tesla’s...
A noted market analyst warns that Strategy’s aggressive Bitcoin purchases echo dot-com-era speculation, risking a ste...
Mortgage lenders accelerate the shift to digital promissory notes as funding timelines tighten. The trend signals eno...
ZachXBT has named Axiom in a probe over alleged insider trading by an employee. Axiom paused internal tools and says ...
Massachusetts lawmakers move to require mandatory fair housing education for real estate licensees, setting a new thr...
Prediction-market trading on Iran’s leadership surged as tensions flared, but unverified rumors triggered rapid price...
Bitcoin bounced off a rough patch, but a veteran trader cautions that a final flush could wipe out late buyers. Analy...
The FDA is piloting cash bonuses to reward reviewers who finish drug evaluations faster while preserving scientific r...
ExxonMobil and Chevron are rallying as investors price in a richer oil regime, with big-cap budgets and buyback plans...
When the PC market slows, smart investors look beyond laptops. A new wave of winners emerges—from memory makers to AI...
T-Mobile US leads on postpaid customer growth and cash flow, while Vodafone accelerates cross-border restructuring an...